Immunovant, Inc. logo

Immunovant, Inc.

NASDAQ:IMVT

Overview | Financials
Company Name Immunovant, Inc.
Symbol IMVT
Currency USD
Price 25.86
Market Cap 3,795,860,100
Dividend Yield 0%
52-week-range 24.61 - 45.58
Industry Biotechnology
Sector Healthcare
CEO Dr. Peter Salzmann M.B.A., M.D.
Website https://immunovant.com

An error occurred while fetching data.

About Immunovant, Inc.

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid

Related Stocks

Atara Biotherapeutics, Inc. logo

Atara Biotherapeutics, Inc.

ATRA

11.4 USD

Immatics N.V. logo

Immatics N.V.

IMTX

6.85 USD

Karyopharm Therapeutics Inc. logo

Karyopharm Therapeutics Inc.

KPTI

0.635 USD

Nautilus Biotechnology, Inc. logo

Nautilus Biotechnology, Inc.

NAUT

1.76 USD

2seventy bio, Inc. logo

2seventy bio, Inc.

TSVT

3.14 USD

Nurix Therapeutics, Inc. logo

Nurix Therapeutics, Inc.

NRIX

19.83 USD

Arcturus Therapeutics Holdings Inc. logo

Arcturus Therapeutics Holdings Inc.

ARCT

15.48 USD

Cara Therapeutics, Inc. logo

Cara Therapeutics, Inc.

CARA

0.423 USD

MaxCyte, Inc. logo

MaxCyte, Inc.

MXCT

4.24 USD

Financials

Numbers are in millions USD

Numbers are in millions USD